Last reviewed · How we verify
loteprednol etabonate and tobramycin
loteprednol etabonate and tobramycin is a Aminoglycoside Antibacterial [EPC] Small molecule drug developed by Bausch & Lomb Incorporated. It is currently FDA-approved for Steroid-responsive inflammatory ocular conditions, Inflammatory conditions of the palpebral and bulbar conjunctiva, Chronic anterior uveitis. Also known as: Zylet.
At a glance
| Generic name | loteprednol etabonate and tobramycin |
|---|---|
| Also known as | Zylet |
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | Aminoglycoside Antibacterial [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Steroid-responsive inflammatory ocular conditions
- Inflammatory conditions of the palpebral and bulbar conjunctiva
- Chronic anterior uveitis
- Corneal injury from chemical, radiation, or thermal burns
- Penetration of foreign bodies in the eye
Common side effects
- injection
- superficial punctate keratitis
- increased intraocular pressure
- burning and stinging upon instillation
Key clinical trials
- Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial (PHASE1)
- A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis (PHASE4)
- Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis (PHASE4)
- Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis (PHASE4)
- Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis (PHASE3)
- Zylet vs TobraDex in Blepharokeratoconjunctivitis (PHASE4)
- Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex (PHASE4)
- Pediatric Zylet Safety and Efficacy Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- loteprednol etabonate and tobramycin CI brief — competitive landscape report
- loteprednol etabonate and tobramycin updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI
Frequently asked questions about loteprednol etabonate and tobramycin
What is loteprednol etabonate and tobramycin?
loteprednol etabonate and tobramycin is a Aminoglycoside Antibacterial [EPC] drug developed by Bausch & Lomb Incorporated, indicated for Steroid-responsive inflammatory ocular conditions, Inflammatory conditions of the palpebral and bulbar conjunctiva, Chronic anterior uveitis.
What is loteprednol etabonate and tobramycin used for?
loteprednol etabonate and tobramycin is indicated for Steroid-responsive inflammatory ocular conditions, Inflammatory conditions of the palpebral and bulbar conjunctiva, Chronic anterior uveitis, Corneal injury from chemical, radiation, or thermal burns, Penetration of foreign bodies in the eye.
Who makes loteprednol etabonate and tobramycin?
loteprednol etabonate and tobramycin is developed and marketed by Bausch & Lomb Incorporated (see full Bausch & Lomb Incorporated pipeline at /company/bausch-lomb-incorporated).
Is loteprednol etabonate and tobramycin also known as anything else?
loteprednol etabonate and tobramycin is also known as Zylet.
What drug class is loteprednol etabonate and tobramycin in?
loteprednol etabonate and tobramycin belongs to the Aminoglycoside Antibacterial [EPC] class. See all Aminoglycoside Antibacterial [EPC] drugs at /class/aminoglycoside-antibacterial-epc.
What development phase is loteprednol etabonate and tobramycin in?
loteprednol etabonate and tobramycin is FDA-approved (marketed).
What are the side effects of loteprednol etabonate and tobramycin?
Common side effects of loteprednol etabonate and tobramycin include injection, superficial punctate keratitis, increased intraocular pressure, burning and stinging upon instillation.
Related
- Drug class: All Aminoglycoside Antibacterial [EPC] drugs
- Manufacturer: Bausch & Lomb Incorporated — full pipeline
- Indication: Drugs for Steroid-responsive inflammatory ocular conditions
- Indication: Drugs for Inflammatory conditions of the palpebral and bulbar conjunctiva
- Indication: Drugs for Chronic anterior uveitis
- Also known as: Zylet
- Compare: loteprednol etabonate and tobramycin vs similar drugs
- Pricing: loteprednol etabonate and tobramycin cost, discount & access